SANGAMO THERAPEUTICS INC (SGMO)
US8006771062 - Common Stock
What's going on in today's after hours session
Curious about the stocks that are showing activity after the closing bell on Tuesday?
A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease.
RBC Capital downgrades Sangamo as biotech moves to save cash (SGMO)
RBC Capital downgrades Sangamo Therapeutics (SGMO) due to workforce cuts and program pauses, lowering price target to $2 from $6. Read more here.
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares (NASDAQ:SGMO)
Sangamo Therapeutics (SGMO) sells 6 million shares for $3 million, according to recent disclosure.
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
Notable Wednesday Option Activity: OXY, SGMO, ZM
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Commit To Buy Sangamo Therapeutics At $1, Earn 18.6% Annualized Using Options
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Tuesday Sector Leaders: Banking & Savings, Biotechnology Stocks
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
Sangamo downgraded to underperform at BofA on restructuring (NASDAQ:SGMO)
BofA Securities has downgraded Sangamo Therapeutics (SGMO) to underperform as the company is undergoing a restructuring to address cash concerns. Read more here.